(Q43568188)

24 November 2017

Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders (English)

1 reference

24 November 2017

2

1 reference

24 November 2017

Bauer M

1

1 reference

24 November 2017

Berghöfer A

3

1 reference

24 November 2017

Bschor T

4

1 reference

24 November 2017

Kiesslinger U

5

1 reference

24 November 2017

Whybrow PC

6

1 reference

24 November 2017

1 April 2001

1 reference

Journal of Affective Disorders

24 November 2017

1 reference

24 November 2017

64

1 reference

24 November 2017

1

1 reference

24 November 2017

35-42

1 reference

Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Treatment of refractory depression with high-dose thyroxine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

[Therapeutic strategies in refractory bipolar disorder]

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Treatment of bipolar depressive mood disorders: Algorithms for pharmacotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Initial response to active drug and placebo predicts outcome of antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Do different subjective evaluation criteria reflect distinct constructs?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Treatment of refractory chronic depression and dysthymia with high-dose thyroxine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Bipolar mood disorder: practical strategies for acute and maintenance phase treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Should thyroid augmentation precede lithium augmentation--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2800%2900215-9

7 January 2021

10.1016/S0165-0327(00)00215-9

Identifiers

DOI

1 reference

24 November 2017

1 reference